- VectivBio Holding ( NASDAQ: VECT ) prices an underwritten offering of 16.7M ordinary shares at an offering price of $7.50/share for gross proceeds of ~$125M.
- The offering is expected to close on or about October 17, 2022.
- The company intends to use the net proceeds from the offering, together with its existing cash and cash equivalents: to fund clinical development and pre-commercialization activities for its lead product candidate and general corporate purposes, including general and administrative expenses and working capital.
- Shares are trading higher 13% premarket.
For further details see:
VectivBio gains on pricing of $125M underwritten offering of ordinary shares